Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History SNGX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics SNGX

Max Ratio

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Forward Annual Dividend Yield
Consecutive Years
Forward Annual Dividend – USD
Consistent Years
Dividend CAGR 3Y
Continuous Dividends
Dividend CAGR 5Y
Payout Ratio TTM
Dividend CAGR 10Y
Ex Dividend Date

Soligenix Inc

SNGX
Current price
1.27 USD 0 USD (0.00%)
Last closed 1.27 USD
ISIN US8342233074
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 4 212 056 USD
Yield for 12 month -81.49 %
1Y
3Y
5Y
10Y
15Y
SNGX
21.11.2021 - 28.11.2021

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of products to treat rare diseases in the United States. It operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a photodynamic therapy, which has completed Phase 3 clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator (IDR) technology that is in Phase 3 clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX945, an IDR technology that is in Phase 2a study to treat aphthous ulcers in Behçet's disease; and SGX302, an IDR technology, which is in Phase 2a study for the treatment of mild-to-moderate psoriasis. Its Public Health Solutions segment engages in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase 1a, 1b, and 1c clinical trials; SGX943, a therapeutic candidate in preclinical studies for the treatment of antibiotic-resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; CiVax, a vaccine candidate for the prevention of COVID-19; and vaccine programs that target filoviruses, such as Marburg and Ebola. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in September 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey. Address: 29 Emmons Drive, Princeton, NJ, United States, 08540

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

35.00 USD

P/E Ratio

Dividend Yield

Financials SNGX

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures SNGX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

+119 371 USD

Last Year

+839 359 USD

Current Quarter

Last Quarter

+6 352 USD

Current Year

-125 000 USD

Last Year

+97 311 USD

Current Quarter

Last Quarter

EBITDA -10 629 575 USD
Operating Margin TTM -454 073.83 %
Price to Earnings
Return On Assets TTM -84.11 %
PEG Ratio -1.52
Return On Equity TTM -437.73 %
Wall Street Target Price 35.00 USD
Revenue TTM 2 342 USD
Book Value 1.14 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY -100.00 %
Dividend Yield
Gross Profit TTM
Earnings per share -3.13 USD
Diluted Eps TTM -3.13 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY
Profit Margin

Stock Valuation SNGX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 1.87
Price Sales TTM 1 798.49
Enterprise Value EBITDA -0.12
Price Book MRQ 1.13

Technical Indicators SNGX

For 52 Weeks

1.09 USD 7.61 USD
50 Day MA 1.74 USD
Shares Short Prior Month 24 668
200 Day MA 2.62 USD
Short Ratio 1.13
Shares Short 83 293
Short Percent 0.76 %